Targeted agents, including anti-IL-1 (anakinra and canakinumab), anti-IL-6 (tocilizumab), anti-tumor necrosis factor α (TNF-α) (adalimumab, infliximab, and etanercept), and Janus kinase inhibitors, have been proposed as possible treatments for VEXAS syndrome (2–4). This evidence concerns the gene TNF and VEXAS syndrome.